康艾注射液联合新辅助化疗治疗三阴型乳腺癌的临床疗效研究  

Clinical efficacy of Kangai injection combined with neoadjuvant chemotherapy in the treatment of triple-negative breast cancer

作　　者：曹宇华[1] 莫艳芳[2] 吕艳茹[1] CAO Yu-hua;MO Yan-fang;L Yan-ru(The First Chemotherapy Area,the People’s Hospital of Guangxi Zhuang Autonomous Region,Nanning 530021,China;National Hospital of Guangxi Zhuang Autonomous Region/Affiliated National Hospital of Guangxi Medical University,Nanning 530001,China)

机构地区：[1]广西壮族自治区人民医院临床肿瘤中心化疗一区,广西南宁530021 [2]广西壮族自治区民族医院/广西医科大学附属民族医院,广西南宁530001

出　　处：《实用药物与临床》2021年第5期437-440,共4页Practical Pharmacy and Clinical Remedies

基　　金：国家自然科学基金(地区基金项目)(81960482)。

摘　　要：目的探讨康艾注射液联合新辅助化疗治疗三阴型乳腺癌的临床疗效。方法2016年12月1日-2019年12月1日我院收治的70例新辅助化疗女性三阴型乳腺癌患者,随机分为观察组和对照组,观察组应用新辅助化疗联合康艾注射液,对照组患者应用新辅助化疗治疗。对比两组患者的近期疗效、远期疗效、生存质量、肿瘤标志物水平、免疫水平及不良反应。结果治疗后,观察组临床缓解率高于对照组(60%vs.51.4%),观察组疾病控制率高于对照组(88.6%vs.85.7%),但两组差异无统计学意义(P>0.05)。观察组患者中位无进展生存期为6.2个月(95%CI:5.87~6.53),对照组为4.8个月(95%CI:3.93~5.67),两组比较差异无统计学意义(P>0.05)。生存质量评分比较,两组均优于治疗前(P<0.05),且治疗后观察组优于对照组,两组比较差异有统计学意义(P<0.05)。与治疗前相比,两组治疗后肿瘤标志物均明显下降(P<0.05);且观察组下降水平明显低于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,观察组CD 3+、CD 4+、CD 4+/CD 8+水平明显升高,CD 8+则显著降低,与对照组相比,差异有统计学意义(P<0.05)。两组患者各项毒副作用发生率比较差异无统计学意义(P>0.05)。结论康艾注射液联合新辅助化疗治疗三阴型乳腺癌可有效改善乳腺癌患者的生存质量,降低肿瘤标志物水平,提升患者免疫功能。Objective To investigate the clinical efficacy and adverse reactions of Kangai injection combined with neoadjuvant chemotherapy in the treatment of triple-negative breast cancer.Methods Seventy female patients with triple-negative breast cancer who were treated with neoadjuvant chemotherapy from December 1,2016 to December 1,2019 were included in the study.The patients were randomly divided into observation group and control group.Patients in the observation group were treated with neoadjuvant chemotherapy combined Kangai injection.Patients in the control group were treated with neoadjuvant chemotherapy.The short-term efficacy,long-term efficacy,quality of life,tumor marker level,immune level and adverse reactions were compared between the two groups.Results After treatment,the clinical remission rate of the observation group was 60.0%,which was slightly higher than 51.4%of the control group;the disease control rate of the observation group was 88.6%,which was slightly higher than 85.7%of the control group,but the difference was not statistically significant(P>0.05).The median progression-free survival time of patients in the observation group was 6.2 months(95%CI:5.87~6.53),and in the control group it was 4.8 months(95%CI:3.93~5.67)and no statistical difference was found(P>0.05).The quality-of-life scores of the two groups were better than those before treatment(P<0.05),the observation group being better than the control group,and the difference between the two groups was significant(P<0.05).The tumor markers of the two groups were significantly decreased after treatment(P<0.05);the decrease in observation group group was greater than that in control group,and the difference between the groups was significant(P<0.05).After treatment,the levels of CD 3+,CD 4+,and CD 4+/CD 8+in the observation group were significantly increased,while the level of CD 8+was significantly decreased.Compared with the control group,the difference was significant(P<0.05).There was no significant difference in the incidence of toxic and

关 键 词：康艾注射液 新辅助化疗 三阴乳腺癌 不良反应 

分 类 号：R737.9[医药卫生—肿瘤]